Visual prognosis appears generally good after PPV for retained lens material

Article

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well.

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well, said Lawrence Y. Ho, MD.

Dr. Ho reported the findings from a retrospective review that included analyses for predictors of good and poor visual outcomes. The series included 166 consecutive cases from a 6-year period extending from January 2001 to January 2007. Follow-up exceeded 6 months in more than 80% of eyes. The visual results showed 72% of eyes achieved vision of 20/40 or better while only 10.8% ended up with vision of 20/200 or worse.

"The outcomes in this series surpass those in prior large series that showed only 58% of patients had vision of 20/40 or better while almost 18% saw 20/200 or worse. We believe improvements in both phaco technology and vitrectomy combined with earlier detection of treatment complications, such as CME with more widespread use of OCT, may account for the difference. However, this warrants further investigation," said Dr. Ho.

Predictors of vision outcomes were examined in a multivariate analysis. Better presenting vision, insertion of a posterior chamber IOL, and absence of preoperative eye disease were associated with a good vision outcome.

Development of glaucoma and presence of preexisting eye disease were associated with a poor vision outcome while anterior vitrectomy at the time of cataract surgery and sulcus lens placement at cataract surgery had protective value.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.